Stock · IDXX · Healthcare
United States · Large Cap · listed since 1991 · Revenue 12 mo. $4.6B
Price as of 11/06/2026
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Original text from the data provider
Summary
52.5 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €945.3M (2025), it supports €10.5B. The remaining €28.7B of the market value assume it grows 18.4% a year for 10 years and not at all afterwards.
Required FCF growth per year
18.4%
no growth afterwards
Price to operating cash flow 39.9×, below its usual range.
Middle half of 20 quarters: 43.7× to 58.1×, median 47.7×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q2 2026
6 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 65.99% | 11.52% | Rank 96 |
| Return on capital (Greenblatt) | 128.06% | 32.55% | Rank 95 |
| EBIT margin | 31.60% | 18.31% | Rank 88 |
| FCF margin | 24.48% | 14.12% | Rank 84 |
| Gross margin | 61.80% | 60.99% | Rank 51 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 10.42% | 8.04% | Rank 63 |
| Earnings growth, 3 years per year | 17.83% | 5.44% | Rank 73 |
| Earnings growth, 5 years per year | 14.38% | 7.00% | Rank 67 |
| Sustainable growth (ROE × retained earnings) | 2.90% | 3.66% | Rank 36 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 1.94% | 2.90% | Rank 27 |
| FCF yield | 2.41% | 3.63% | Rank 29 |
| EV/saleslower is better | 10.36 | 4.03 | Rank 13 |
| EV/EBITlower is better | 32.80 | 21.73 | Rank 24 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −14.89% | 8.66% | Rank 24 |
| Share price, 6 months | 21.18% | 24.27% | Rank 46 |
| Share price, 3 months | 20.36% | 15.42% | Rank 67 |
| Distance from 52-week high | −11.82% | −7.35% | Rank 35 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 0.53% | 0.30% | Rank 46 |
| Change in share countlower is better | −2.87% | 0.00% | Rank 89 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | 22.09% | 0.05% | Rank 100 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 47.91% | 48.40% | Rank 49 |
| Net debt/EBITDAlower is better | 0.60 | 1.11 | Rank 61 |
| Debt to equitylower is better | 0.67 | 0.48 | Rank 39 |
| Volatility, 1 yearlower is better | 39.25% | 31.42% | Rank 28 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 1.8 | 19.7% | $269.8M | 90.9M | $1.0B |
| 2017 | 2.0 | 21.0% | $296.6M | 89.6M | $1.1B |
| 2018 | 2.2 | 22.2% | $277.1M | 88.5M | $876.5M |
| 2019 | 2.4 | 23.0% | $303.9M | 87.5M | $980.1M |
| 2020 | 2.7 | 25.7% | $540.4M | 86.7M | $619.3M |
| 2021 | 3.2 | 29.0% | $636.0M | 86.6M | $886.6M |
| 2022 | 3.4 | 26.7% | $394.1M | 84.6M | $1.4B |
| 2023 | 3.7 | 30.0% | $772.9M | 84.0M | $613.4M |
| 2024 | 3.9 | 29.0% | $798.1M | 83.1M | $698.6M |
| 2025 | 4.3 | 31.6% | $1.1B | 80.7M | $897.1M |
4 of 7 StockScorer Score rules met · How the score is built
IDEXX Laboratories Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
IDEXX Laboratories Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for IDEXX Laboratories Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 51.5 | 30.0 |
| P/B ratio | 34.0 | 4.8 |
| Return on equity (ROE) | 66.0% | 11.5% |
| Equity ratio | 47.9% | 48.4% |
| Debt-to-equity (D/E) | 0.67 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| IDXX | IDEXX Laboratories Incthis page | |
| WAT | Waters Corporation | Low4.5 |
| IQV | IQVIA Holdings Inc | Low4.5 |
| NTRA | Natera Inc | locked |
| A | Agilent Technologies Inc | locked |
| ILMN | Illumina Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.